TherapeuticsMD (TXMD) Common Equity (2016 - 2025)
Historic Common Equity for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $27.4 million.
- TherapeuticsMD's Common Equity rose 129.18% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 129.18%. This contributed to the annual value of $27.4 million for FY2024, which is 654.56% down from last year.
- TherapeuticsMD's Common Equity amounted to $27.4 million in Q3 2025, which was up 129.18% from $27.3 million recorded in Q2 2025.
- In the past 5 years, TherapeuticsMD's Common Equity ranged from a high of $35.1 million in Q4 2022 and a low of -$140.6 million during Q1 2022
- For the 5-year period, TherapeuticsMD's Common Equity averaged around -$4.0 million, with its median value being $27.3 million (2025).
- In the last 5 years, TherapeuticsMD's Common Equity crashed by 138322.43% in 2022 and then surged by 21968.46% in 2023.
- Over the past 5 years, TherapeuticsMD's Common Equity (Quarter) stood at -$93.6 million in 2021, then soared by 137.54% to $35.1 million in 2022, then decreased by 16.66% to $29.3 million in 2023, then dropped by 6.55% to $27.4 million in 2024, then rose by 0.27% to $27.4 million in 2025.
- Its last three reported values are $27.4 million in Q3 2025, $27.3 million for Q2 2025, and $26.7 million during Q1 2025.